Placebo News and Research

RSS

Acupuncture could be a safe and feasible management option for IBS-D

Researchers preliminarily evaluated the practicality of utilizing the United States (US) Food and Drug Administration (FDA)-advocated endpoints to assess the effectiveness of acupuncture in IBS-D (irritable bowel syndrome with diarrhea) management.

5 Jan 2023

Study demonstrates safety and efficacy of a three-dose whole-parasite vaccine against malaria

A three-dose regimen of a whole-parasite vaccine against malaria – called Plasmodium falciparum sporozoite (PfSPZ) vaccine – demonstrated safety and efficacy when tested in adults living in Burkina Faso, West Africa, which has endemic malaria.

4 Jan 2023

How could probiotics be used in the management of gingivitis and periodontitis?

New research explores how probiotic-based therapy in conjunction with established treatment regimens can be an effective approach for combating gingivitis and periodontitis.

28 Dec 2022

Molnupiravir does not reduce hospitalization or deaths in vaccinated adults with COVID-19, but improves recovery

Molnupiravir (taken as an 800mg dose twice daily for five days) does not reduce hospital admissions or deaths in vaccinated adults with COVID-19 infection who are at higher risk of mortality, according to the results of a randomised controlled trial, published in The Lancet journal.

23 Dec 2022

Clinical trials demonstrate safety and efficacy of Ebola Zaire vaccines

Two vaccines against the Zaire strain of Ebola virus are immunogenic and safe in both adults and children, according to initial results from two phase II clinical trials published in the New England Journal of Medicine.

21 Dec 2022

Trial of three vaccines for Zaire Ebola virus disease

Researchers perform two randomized controlled trials to determine immunogenicity and safety of three Ebola vaccines.

20 Dec 2022

Can ivermectin improve the duration of sustained recovery among COVID-19 outpatients?

Researchers assessed the impact of ivermectin on the duration of sustained recovery among coronavirus disease 2019 (COVID-19) outpatients.

20 Dec 2022

Dapagliflozin improves morbidity reduces risk of death in heart failure patients

Researchers investigate the safety and efficacy of dapagliflozin among heart failure patients with improved ejection fraction.

19 Dec 2022

Low ET levels in blood plasma may predict increased risk of cognitive impairment, dementia

A recent study by a team comprising researchers from the National University of Singapore and the National University Health System revealed that low levels of ergothioneine in blood plasma may predict an increased risk of cognitive impairment and dementia, suggesting possible therapeutic or early screening measures for cognitive impairment and dementia in the elderly.

19 Dec 2022

Trial results confirm the safety of three different Ebola vaccine regimens

Ebola epidemics occur periodically in various sub-Saharan African countries. While vaccines exist and have already received WHO Prequalification against the Zaire ebolavirus species, it is essential to pursue and intensify efforts to supplement the available data to develop a safe and effective Ebola vaccine strategies in adults and children alike.

16 Dec 2022

Walnut consumption has positive effects on stressed university students

Stressed university students might want to add walnuts to their daily diet in the weeks leading up to their next exam.

16 Dec 2022

Randomized trials demonstrate the safety of Ebola vaccine regimens in adults and children

Two randomized, placebo-controlled trials evaluating three Ebola vaccine administration strategies in adults and children found that all the regimens were safe in both age groups, according to results published today in the New England Journal of Medicine.

15 Dec 2022

The therapeutic effects and safety of psychedelics

Psychedelics are reported to have rapid-onset and long-lasting therapeutic benefits after a single or few doses.

14 Dec 2022

The effectiveness of nirmatrelvir-ritonavir and molnupiravir for the treatment of COVID-19 among US veterans

Researchers evaluated the effectiveness of SARS-CoV-2 antivirals, nirmatrelvir-ritonavir, and molnupiravir among Veterans in the United States of America.

13 Dec 2022

Clinical efficacy and safety of two injections of a bivalent vaccine as a primary series during a period of Omicron circulation

Researchers evaluated the bivalent vaccine efficacy against the Omicron VOC.

13 Dec 2022

Novel monoclonal antibody therapy shows promising results in patients with moderate to severe atopic dermatitis

Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab-;a novel, patient-tailored monoclonal antibody therapy-;showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers reported in The Lancet.

12 Dec 2022

$Forxiga (dapagliflozin) approved in Great Britain for symptomatic chronic heat failure across the full spectrum of left ventricular ejection fraction$

Forxiga (dapagliflozin) approved in Great Britain for symptomatic chronic heat failure across the full spectrum of left ventricular ejection fraction

AstraZeneca today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a licence extension for dapagliflozin in Great Britain for the treatment of symptomatic chronic heart failure (HF) in patients with HF and a left ventricular ejection fraction (LVEF) >40%, including HF with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF).

From AstraZeneca 12 Dec 2022

Study shows potential benefits of efgartigimod as a treatment for immune thrombocytopenia

Patients taking efgartigimod, a drug being studied for use to treat chronic primary immune thrombocytopenia (ITP), exhibited a significantly greater improvement in platelet counts which are essential to clotting and stopping bleeding, compared to those taking a placebo, according to results reported from the ADVANCE IV clinical trial, which was conducted globally, including at Georgetown University Medical Center.

12 Dec 2022

Addition of capivasertib to fulvestrant doubles progression-free survival in HR-positive breast cancer patients

In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled the median progression-free survival compared with placebo plus fulvestrant in the phase III CAPItello-291 clinical trial, according to results presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

9 Dec 2022

Researchers gain new insights into ADHD drug's mechanism of action

For decades, doctors have treated kids with attention-deficit/hyperactivity disorder (ADHD) with methylphenidate, a stimulant drug sold as Ritalin and Concerta, making it one of the most widely prescribed medications aimed at the central nervous system.

8 Dec 2022